Loading clinical trials...

BOTOX® in the Treatment of Crow's Feet Lines in Japan | Clinical Trials | Clareo Health

COMPLETEDPHASE3

BOTOX® in the Treatment of Crow's Feet Lines in Japan

NCT01797081•Allergan

Summary

This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) compared to placebo for the treatment of Crow's Feet Lines (Lateral Canthus Rhytides).

Eligibility

Age

20 - 64 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Moderate to severe Crow's Feet Lines

Exclusion Criteria

•Current or previous botulinum toxin treatment of any serotype
•Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis
•Facial laser or light treatment for cosmetic purposes, microdermabrasion, superficial peels, or topical retinoid therapy or hormone cream within 3 months
•Laser treatment or phototherapy of the face for medical purposes, blepharoplasty, brow-lift or related procedure, periorbital permanent make-up, or oral retinoid therapy within one year
•Medium-depth or deep facial peels within 5 years
•Prior facial cosmetic surgery (e.g., prior periorbital surgery, facial lift, periorbital treatment with fillers, implantation or transplantation)

Locations (1)

Tokyo, Japan

Key Dates

Start Date

January 31, 2013

Primary Completion Date

July 18, 2013

Completion Date

July 7, 2014

Last Updated

April 16, 2019

Enrollment

300

ACTUAL participants

Conditions

Lateral Canthus RhytidesCrow's Feet Lines

Interventions

botulinum toxin Type A (24 U)

BIOLOGICAL

botulinum toxin Type A (12 U)

BIOLOGICAL

Normal Saline

OTHER

A Study Comparing DMSB01 and Rejuran® for Temporary Crow's Feet Lines Improvement

NCT06402058

Crow's Feet Lines

View study

COMPLETEDPHASE3

Evaluate the Safety and Efficacy of Botulax® as Compared to Botox® in Subject With Moderate to Severe Crow's Feet Lines

NCT03408236

Crow's Feet Lines

View study

COMPLETEDPHASE4

Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 16, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

BOTOX® in the Treatment of Crow's Feet Lines in Japan

Inclusion Criteria

Exclusion Criteria

A Study Comparing DMSB01 and Rejuran® for Temporary Crow's Feet Lines Improvement

Evaluate the Safety and Efficacy of Botulax® as Compared to Botox® in Subject With Moderate to Severe Crow's Feet Lines

Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)

Efficacy and Safety of DWP450 for Treating Crows Feet Lines(CFL) in Combination With Glabellar Lines(Extension Study)

BOTOX® in the Treatment of Upper Facial Lines in Japan

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines